The Jupiter Trial slides results

Dr Ridker discusses new findings from the JUPITER trial which were initially released at the American College of Cardiology meeting in March ‘09. As was previously reported in the New England Journal of Medicine, treatment with rosuvastatin significantly reduced vascular event rates in individuals with normal levels of LDL cholesterol...

High hsCRP levels have been found to be associated with poor cardiovascular outcomes in patients with acute coronary syndrome (ACS). There are however few data and some conflicting data with regards to ST elevation MI, the full spectrum of ACS, specific subgroups of patients with ACS, and the timing of measurement of CRP. The purpose of the...

Recently, new insights have become available into how anti-inflammatory effects of statin treatment impact on what happens within the coronary arteries. As seen in the REVERSAL trial, for example, a reduction in systemic inflammation, as indicated by the level of C-reactive protein, was important in addition to cholesterol-lowering, for the...

Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score

This article describes how the Reynolds Risk Score was developed and validated using data from 24,558 initially healthy American women, who were followed up for a median of 10.2 years for incident cardiovascular events.

Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial

New data from almost 4000 patients with ACS demonstrating the clinical utility of hs-CRP measured at 30 days or 4 months of follow-up, in terms of predicting 2-year mortality.

Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein - Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)

Black tea reduces uric acid and C-reactive protein levels in humans susceptible to cardiovascular diseases.

Relation of Left Ventricular Hypertrophy With Systemic Inflammation and Endothelial Damage in Resistant Hypertension

C-Reactive Protein and Incident Left Ventricular Hypertrophy in Essential Hypertension

Health screening packages: the place of measuring C-reactive protein.

Should high sensitive C-reactive protein measurement be included in health screening packages?

Association of inflammation with worsening HOMA-insulin resistance.

C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: Inhibitory effects of atorvastatin

Reduced high-molecular weight adiponectin and elevated hsCRP are synergistic risk factors for metabolic syndrome in a large scale middle-aged to elderly population: the J-SHIPP study

High-sensitivity C-reactive protein predicts target organ damage in Chinese patients with metabolic syndrome

High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation. Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis

C-Reactive Protein, Carotid Atherosclerosis, and Cerebral Small-Vessel Disease

Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984–1998

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH

New Findings From JUPITER Show Rosuvastatin Cuts Stroke Risk in Half Among Those With Elevated CRP Levels and Commonly Acceptable Cholesterol Levels

FDA Panel Backs Statin for Primary Prevention